Streptavidin-ZAP evaluates antibodies for targeted tumor treatment

Characterization of the First Fully Human Anti-Tem1 Scfv in Models of Solid Tumor Imaging and Immunotoxin-Based Therapy. Yuan, X, Yang, M, Chen, X, et al. (2018). Cancer Immunol Immunother 2018/01/10.

Streptavidin-ZAP (Cat. #IT-27)

Objective: ScFv78 was conjugated with the ribosome-inactivating protein saporin (Streptavidin-ZAP) to evaluate whether scFv78 may be used as a vehicle for theTEM1-targeted delivery of toxins.

Summary: Site-specific, biotinylated scFv78 was conjugated with streptavidin-labeled saporin (Streptavidin-ZAP; Cat. #IT-27) by incubation at room temperature for 1h at a molar ratio of 4:1 (scFv78:ZAP).

Cells were cultured in 96-well plates to 30% confluence and then incubated for 96h in the presence of 10-fold serially diluted Streptavidin-ZAP, scFv78, or scFv78-ZAP starting from 40nM down to 0.04nM. The data indicate that scFv78, the first fully human anti-TEM1 recombinant antibody, recognizes both human and mouse TEM1 and has unique and favorable features that are advantageous for the development of imaging probes or antibody-toxin conjugates for a large spectrum of human TEM1-positive solid tumors.

Shopping Cart
Scroll to Top